Generate Biomedicines (NASDAQ:GENB) Trading 6.6% Higher – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB)’s share price rose 6.6% during trading on Monday . The company traded as high as $17.66 and last traded at $17.5550. 184,085 shares were traded during trading, a decline of 73% from the average session volume of 670,269 shares. The stock had previously closed at $16.47.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GENB. Piper Sandler assumed coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective on the stock. HC Wainwright increased their target price on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 target price for the company. Cantor Fitzgerald started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating on the stock. Finally, Guggenheim initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price objective for the company. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Generate Biomedicines presently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Down 0.2%

The company has a market capitalization of $2.16 billion and a price-to-earnings ratio of -15.77. The firm’s 50 day moving average is $13.94.

Generate Biomedicines (NASDAQ:GENB) last released its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.